trimethyloxamine has been researched along with Stroke in 35 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although trimethylamine-N-oxide (TMAO) shows a notable correlation with cardiovascular disease, its association with acute ischemic stroke (AIS) remains uncertain and necessitates further investigation." | 9.41 | The relationship between trimethylamine-N-oxide and the risk of acute ischemic stroke: A dose‒response meta-analysis. ( Duan, Y; Guo, Z; Hong, Y; Li, Y; Liu, N; Sun, Z; Xu, Q; Yang, K, 2023) |
| "Patients with higher choline and betaine levels had lower risk of cognitive impairment after ischemic stroke, supporting promising prognostic roles of choline pathway nutrients for poststroke cognitive impairment." | 9.41 | Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke. ( Bu, X; Che, B; Ju, Z; Lu, Z; Qian, S; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zheng, X; Zhong, C, 2021) |
| " We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual-antiplatelet therapy and intensive lipid-lowering therapy and with a low inflammation level (high-sensitivity C-reactive protein <2 mg/L on admission)." | 8.12 | Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy. ( Cheng, A; Jiang, X; Jin, A; Li, H; Li, K; Lin, J; Meng, X; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Although trimethylamine-N-oxide (TMAO) shows a notable correlation with cardiovascular disease, its association with acute ischemic stroke (AIS) remains uncertain and necessitates further investigation." | 5.41 | The relationship between trimethylamine-N-oxide and the risk of acute ischemic stroke: A dose‒response meta-analysis. ( Duan, Y; Guo, Z; Hong, Y; Li, Y; Liu, N; Sun, Z; Xu, Q; Yang, K, 2023) |
| "Patients with higher choline and betaine levels had lower risk of cognitive impairment after ischemic stroke, supporting promising prognostic roles of choline pathway nutrients for poststroke cognitive impairment." | 5.41 | Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke. ( Bu, X; Che, B; Ju, Z; Lu, Z; Qian, S; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zheng, X; Zhong, C, 2021) |
| "Increased TMAO was associated with higher stroke risk in the community-based population, whereas the TMAO precursors carnitine, choline, betaine, and TML were not associated." | 4.31 | Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study. ( Gu, S; Liu, D; Ma, Z; Zhou, Z; Zuo, H, 2023) |
| "There is increasing evidence for the association of trimethylamine-N-oxide (TMAO) with cognitive impairment after minor stroke or transient ischemic attack (TIA)." | 4.31 | Association between plasma trimethylamine-N-oxide and cognitive impairment in patients with transient ischemic attack. ( Bao, Y; Huang, D; Jiang, L; Qv, S; Wang, J; Wang, L; Xu, G; Yang, J; Zhan, X, 2023) |
| " We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual-antiplatelet therapy and intensive lipid-lowering therapy and with a low inflammation level (high-sensitivity C-reactive protein <2 mg/L on admission)." | 4.12 | Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy. ( Cheng, A; Jiang, X; Jin, A; Li, H; Li, K; Lin, J; Meng, X; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Increased levels of lactic acid, pyruvate, and TMAO may be related to the pathophysiological changes in the minor ischaemic stroke population." | 4.12 | Related factors based on non-targeted metabolomics methods in minor ischaemic stroke. ( Chen, C; Ding, L; Guo, J; Liu, H; Ma, Y; Qiao, X; Wang, J; Wang, M; Yang, T; Zhao, S, 2022) |
| "A total of 64 patients with acute ischemic stroke were randomized into an observation group and a control group, 32 cases in each one." | 3.11 | [ ( Du, XZ; Lei, SQ; Liu, MK; Wang, H; Yuan, B, 2022) |
| "As we know, ischemic stroke is a heterogeneous disease with variable pathogenesis." | 2.82 | Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes. ( Cheng, A; Dai, L; Jing, J; Li, H; Meng, X; Song, B; Wang, A; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| " This study aimed to review the available scientific evidence about the relationship between TMAO levels and the risk of stroke in a dose-response meta-analysis." | 2.82 | Plasmatic trimethylamine N-oxide and its relation to stroke: A systematic review and dose-response meta-analysis. ( Chen, P; Guo, Z, 2022) |
| " Dose-response meta-analysis revealed that the relative risk (RR) for all-cause mortality increased by 7." | 2.55 | Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. ( Esposito, G; Franzone, A; Gargiulo, G; Giugliano, G; Perrino, C; Sannino, A; Schiattarella, GG; Toscano, E; Trimarco, B, 2017) |
| "Stroke is the second most common cause of cognitive impairment and dementia." | 1.91 | Exploratory Transcriptomic Profiling Reveals the Role of Gut Microbiota in Vascular Dementia. ( Buffa, J; Kaur, N; LaForce, G; Li, XS; Mallela, DP; Rothenberg, K; Saha, PP; Sangwan, N; Zhu, W, 2023) |
| " Trimethylamine N-oxide level, Acute ischemic stroke, Early neurological deterioration, NIHSS score." | 1.91 | Utility of Trimethylamine Oxide (TMAO) in Predicting Early Neurological Deterioration after Acute Ischemic Stroke. ( Cheng, H; Kang, Y; Liu, J; Shi, Y; Wan, D; Wang, Y, 2023) |
| "TMAO was associated with lacunar stroke but not other ischemic stroke subtypes in a model adjusted for age, sex, hypertension, diabetes, and smoking (OR, 1." | 1.91 | Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke. ( Ament, Z; Bevers, MB; Bhave, VM; Couch, CA; Garcia Guarniz, AL; Irvin, MR; Kijpaisalratana, N; Kimberly, WT, 2023) |
| "In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors." | 1.51 | Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. ( Ahluwalia, TS; Hansen, TW; Hazen, SL; Jorsal, A; Parving, HH; Pedersen, O; Rossing, P; Tarnow, L; Theilade, S; Tofte, N; Wang, Z; Winther, SA; Øllgaard, JC, 2019) |
| "This dysbiosis was correlated with the severity of the disease." | 1.42 | Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. ( Chen, Q; He, Y; Liao, SX; Liu, FT; Pan, SY; Wang, S; Xia, GH; Yin, J; You, C; Zhou, HW; Zhou, L; Zhu, JJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 22 (62.86) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J | 2 |
| Cheng, A | 2 |
| Song, B | 1 |
| Zhao, M | 2 |
| Xue, J | 2 |
| Wang, A | 2 |
| Dai, L | 1 |
| Jing, J | 1 |
| Meng, X | 2 |
| Li, H | 4 |
| Zheng, L | 2 |
| Wang, Y | 5 |
| Zhang, H | 2 |
| Yao, G | 1 |
| Chen, P | 1 |
| Guo, Z | 2 |
| Wang, H | 2 |
| Lei, SQ | 1 |
| Du, XZ | 1 |
| Yuan, B | 1 |
| Liu, MK | 1 |
| Jin, A | 1 |
| Jiang, X | 2 |
| Li, K | 1 |
| Lin, J | 1 |
| Liu, D | 1 |
| Gu, S | 1 |
| Zhou, Z | 2 |
| Ma, Z | 1 |
| Zuo, H | 1 |
| Chen, C | 2 |
| Qiao, X | 1 |
| Guo, J | 1 |
| Yang, T | 1 |
| Wang, M | 1 |
| Ma, Y | 1 |
| Zhao, S | 1 |
| Ding, L | 1 |
| Liu, H | 2 |
| Wang, J | 2 |
| Tu, R | 1 |
| Xia, J | 1 |
| Lemaitre, RN | 2 |
| Jensen, PN | 2 |
| Mozaffarian, D | 2 |
| Wang, L | 2 |
| Zhan, X | 1 |
| Jiang, L | 1 |
| Xu, G | 1 |
| Bao, Y | 1 |
| Qv, S | 1 |
| Yang, J | 1 |
| Huang, D | 1 |
| Kaur, N | 1 |
| LaForce, G | 1 |
| Mallela, DP | 1 |
| Saha, PP | 1 |
| Buffa, J | 1 |
| Li, XS | 5 |
| Sangwan, N | 2 |
| Rothenberg, K | 1 |
| Zhu, W | 4 |
| Chou, PS | 1 |
| Yang, IH | 1 |
| Kuo, CM | 1 |
| Wu, MN | 1 |
| Lin, TC | 1 |
| Fong, YO | 1 |
| Juan, CH | 1 |
| Lai, CL | 1 |
| Kang, Y | 1 |
| Cheng, H | 1 |
| Shi, Y | 1 |
| Liu, J | 1 |
| Wan, D | 1 |
| Wang, Z | 5 |
| Fretts, AM | 1 |
| Sitlani, CM | 1 |
| Nemet, I | 1 |
| Sotoodehnia, N | 1 |
| de Oliveira Otto, MC | 1 |
| Budoff, M | 1 |
| Longstreth, WT | 1 |
| Psaty, BM | 1 |
| Siscovick, DS | 1 |
| Hazen, SL | 6 |
| Kijpaisalratana, N | 1 |
| Ament, Z | 1 |
| Bevers, MB | 1 |
| Bhave, VM | 1 |
| Garcia Guarniz, AL | 1 |
| Couch, CA | 1 |
| Irvin, MR | 1 |
| Kimberly, WT | 1 |
| Hong, Y | 1 |
| Sun, Z | 1 |
| Liu, N | 1 |
| Yang, K | 1 |
| Li, Y | 2 |
| Xu, Q | 1 |
| Duan, Y | 1 |
| Zhu, C | 1 |
| Li, G | 2 |
| Lv, Z | 1 |
| Li, J | 1 |
| Wang, X | 2 |
| Kang, J | 1 |
| Zhan, C | 1 |
| Gencer, B | 2 |
| Gurmu, Y | 1 |
| Bonaca, MP | 1 |
| Morrow, DA | 1 |
| Cohen, M | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Storey, RF | 1 |
| Johanson, P | 1 |
| Sabatine, MS | 1 |
| Farhangi, MA | 1 |
| Vajdi, M | 1 |
| Asghari-Jafarabadi, M | 1 |
| Zhong, C | 1 |
| Lu, Z | 1 |
| Che, B | 1 |
| Qian, S | 1 |
| Zheng, X | 1 |
| Bu, X | 1 |
| Zhang, J | 1 |
| Ju, Z | 1 |
| Xu, T | 1 |
| Zhang, Y | 1 |
| Xu, D | 1 |
| Zhao, W | 2 |
| Song, J | 1 |
| Yin, L | 1 |
| Wang, K | 1 |
| Wei, L | 1 |
| Xu, Y | 1 |
| Min, B | 1 |
| Tang, N | 1 |
| Yan, S | 1 |
| Leng, H | 1 |
| Xue, Q | 1 |
| Peng, M | 1 |
| Romano, KA | 1 |
| Li, L | 2 |
| Buffa, JA | 1 |
| Prakash, P | 1 |
| Tittle, AN | 1 |
| Fu, X | 1 |
| Androjna, C | 1 |
| DiDonato, AJ | 1 |
| Brinson, K | 1 |
| Trapp, BD | 1 |
| Fischbach, MA | 1 |
| Rey, FE | 1 |
| Hajjar, AM | 1 |
| DiDonato, JA | 1 |
| Schiattarella, GG | 1 |
| Sannino, A | 1 |
| Toscano, E | 1 |
| Giugliano, G | 1 |
| Gargiulo, G | 1 |
| Franzone, A | 1 |
| Trimarco, B | 1 |
| Esposito, G | 1 |
| Perrino, C | 1 |
| Yu, W | 1 |
| Xu, C | 1 |
| Hong, W | 1 |
| Xiao, C | 1 |
| Zhao, Y | 2 |
| Cai, Y | 2 |
| Huang, M | 1 |
| Jin, J | 1 |
| Wu, C | 1 |
| Li, C | 1 |
| Xie, N | 1 |
| Yan, F | 1 |
| Lian, Y | 1 |
| Zhou, L | 2 |
| Xu, X | 2 |
| Liang, Y | 1 |
| Ren, M | 1 |
| Li, S | 1 |
| Cheng, X | 1 |
| Zhang, L | 1 |
| Ma, Q | 1 |
| Song, H | 1 |
| Meng, R | 1 |
| Ji, X | 1 |
| Haghikia, A | 2 |
| Liman, TG | 1 |
| Bledau, N | 1 |
| Schmidt, D | 1 |
| Zimmermann, F | 1 |
| Kränkel, N | 1 |
| Widera, C | 1 |
| Sonnenschein, K | 1 |
| Weissenborn, K | 1 |
| Fraccarollo, D | 1 |
| Heimesaat, MM | 1 |
| Bauersachs, J | 1 |
| Bavendiek, U | 1 |
| Endres, M | 1 |
| Landmesser, U | 1 |
| Nie, J | 1 |
| Xie, L | 1 |
| Zhao, BX | 1 |
| Qiu, B | 1 |
| Zhu, F | 1 |
| Li, GF | 1 |
| He, M | 1 |
| Wang, B | 1 |
| Liu, S | 2 |
| Guo, H | 1 |
| Huo, Y | 1 |
| Hou, FF | 1 |
| Qin, X | 1 |
| Liang, Z | 1 |
| Dong, Z | 1 |
| Guo, M | 1 |
| Shen, Z | 1 |
| Yin, D | 1 |
| Hu, S | 1 |
| Hai, X | 1 |
| Stubbs, JR | 1 |
| Stedman, MR | 1 |
| Long, J | 1 |
| Franchetti, Y | 1 |
| West, RE | 1 |
| Prokopienko, AJ | 1 |
| Mahnken, JD | 1 |
| Chertow, GM | 1 |
| Nolin, TD | 1 |
| Winther, SA | 1 |
| Øllgaard, JC | 1 |
| Tofte, N | 1 |
| Tarnow, L | 1 |
| Ahluwalia, TS | 1 |
| Jorsal, A | 1 |
| Theilade, S | 1 |
| Parving, HH | 1 |
| Hansen, TW | 1 |
| Pedersen, O | 1 |
| Rossing, P | 1 |
| Rexidamu, M | 1 |
| Jin, H | 1 |
| Huang, J | 1 |
| Zhai, Q | 1 |
| Tang, Y | 1 |
| Tian, J | 1 |
| Liu, X | 1 |
| Yin, J | 1 |
| Liao, SX | 1 |
| He, Y | 1 |
| Wang, S | 1 |
| Xia, GH | 1 |
| Liu, FT | 1 |
| Zhu, JJ | 1 |
| You, C | 1 |
| Chen, Q | 1 |
| Pan, SY | 1 |
| Zhou, HW | 1 |
| Skagen, K | 1 |
| Trøseid, M | 1 |
| Ueland, T | 1 |
| Holm, S | 1 |
| Abbas, A | 1 |
| Gregersen, I | 1 |
| Kummen, M | 1 |
| Bjerkeli, V | 1 |
| Reier-Nilsen, F | 1 |
| Russell, D | 1 |
| Svardal, A | 1 |
| Karlsen, TH | 1 |
| Aukrust, P | 1 |
| Berge, RK | 1 |
| Hov, JE | 1 |
| Halvorsen, B | 1 |
| Skjelland, M | 1 |
| Obeid, S | 1 |
| Klingenberg, R | 1 |
| Mach, F | 1 |
| Räber, L | 1 |
| Windecker, S | 1 |
| Rodondi, N | 1 |
| Nanchen, D | 1 |
| Muller, O | 1 |
| Miranda, MX | 1 |
| Matter, CM | 1 |
| Wu, Y | 1 |
| Alamri, HS | 1 |
| Gogonea, V | 1 |
| Chung, YM | 1 |
| Tang, WH | 1 |
| Lüscher, TF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| "Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
| Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.[NCT00794885] | Phase 4 | 20,702 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
7 reviews available for trimethyloxamine and Stroke
| Article | Year |
|---|---|
Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes.
Topics: Atherosclerosis; Humans; Ischemic Stroke; Methylamines; Risk Factors; Stroke | 2022 |
Significant correlation between the gut microbiota-derived metabolite trimethylamine-N-oxide and the risk of stroke: evidence based on 23 observational studies.
Topics: Gastrointestinal Microbiome; Humans; Methylamines; Oxides; Risk Factors; Stroke | 2023 |
Plasmatic trimethylamine N-oxide and its relation to stroke: A systematic review and dose-response meta-analysis.
Topics: Humans; Methylamines; Odds Ratio; Plasma; Risk Factors; Stroke | 2022 |
Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO.
Topics: Choline; Cognitive Dysfunction; Gastrointestinal Microbiome; Humans; Inflammation; Stroke; Thrombosi | 2024 |
The relationship between trimethylamine-N-oxide and the risk of acute ischemic stroke: A dose‒response meta-analysis.
Topics: Humans; Ischemic Stroke; Methylamines; Oxides; Stroke | 2023 |
Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke: a systematic review and dose-response meta-analysis.
Topics: Case-Control Studies; Cross-Sectional Studies; Gastrointestinal Microbiome; Humans; Methylamines; Ri | 2020 |
Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Dose-Response Relationship, Drug; Female; | 2017 |
4 trials available for trimethyloxamine and Stroke
| Article | Year |
|---|---|
[
Topics: Acupuncture Points; Acupuncture Therapy; Brain-Gut Axis; C-Reactive Protein; Humans; Interleukin-17; | 2022 |
Plasma Trimethylamine-
Topics: Aged; Atherosclerosis; Female; Humans; Ischemic Stroke; Methylamines; Oxides; Prospective Studies; R | 2023 |
Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke.
Topics: Aged; Antihypertensive Agents; Brain Ischemia; China; Choline; Cognition; Cognition Disorders; Cogni | 2021 |
Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Biomarkers; Brain Ischemia; Female; Humans; Male; Methylamines; Middle Ag | 2019 |
24 other studies available for trimethyloxamine and Stroke
| Article | Year |
|---|---|
Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy.
Topics: C-Reactive Protein; Choline; Humans; Inflammation; Lipids; Methylamines; Oxides; Platelet Aggregatio | 2022 |
Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study.
Topics: Betaine; Carnitine; Case-Control Studies; Choline; Humans; Stroke | 2023 |
Related factors based on non-targeted metabolomics methods in minor ischaemic stroke.
Topics: Biomarkers; Blood Glucose; Brain Ischemia; C-Reactive Protein; Homocysteine; Humans; Hypertension; I | 2022 |
Letter to the editor about published meta-analysis of TMAO and stroke.
Topics: Gastrointestinal Microbiome; Humans; Oxides; Stroke | 2023 |
Association between plasma trimethylamine-N-oxide and cognitive impairment in patients with transient ischemic attack.
Topics: Aged; Cognitive Dysfunction; Humans; Ischemic Attack, Transient; Male; Oxides; Retrospective Studies | 2023 |
Exploratory Transcriptomic Profiling Reveals the Role of Gut Microbiota in Vascular Dementia.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Dementia, Vascular; Gastrointestinal Microbio | 2023 |
The Prognostic Biomarkers of Plasma Trimethylamine N-Oxide and Short-Chain Fatty Acids for Recanalization Therapy in Acute Ischemic Stroke.
Topics: Adult; Biomarkers; Brain Ischemia; Fatty Acids, Volatile; Humans; Ischemic Stroke; Prognosis; Prospe | 2023 |
Utility of Trimethylamine Oxide (TMAO) in Predicting Early Neurological Deterioration after Acute Ischemic Stroke.
Topics: Biomarkers; Brain Ischemia; Cohort Studies; Humans; Ischemic Stroke; Stroke; United States | 2023 |
Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke.
Topics: Aged; Betaine; Carnitine; Cerebral Small Vessel Diseases; Choline; Cross-Sectional Studies; Female; | 2023 |
Association of plasma trimethylamine-N-oxide levels with post-stroke cognitive impairment: a 1-year longitudinal study.
Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Cognitive Dysfunction; Female; Follow-Up Studie | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
The Relationship of Large-Artery Atherothrombotic Stroke with Plasma Trimethylamine N-Oxide Level and Blood Lipid-Related Indices: A Cross-Sectional Comparative Study.
Topics: Aged; Atherosclerosis; Biomarkers; Cross-Sectional Studies; Female; Humans; Lipids; Male; Methylamin | 2021 |
Gut microbes impact stroke severity via the trimethylamine N-oxide pathway.
Topics: Animals; Bacteria; Choline; Female; Gastrointestinal Microbiome; Humans; Male; Methylamines; Mice; M | 2021 |
Simultaneous determination of trimethylamine N-oxide, choline, betaine by UPLC-MS/MS in human plasma: An application in acute stroke patients.
Topics: Aged; Betaine; Choline; Chromatography, High Pressure Liquid; Female; Humans; Male; Methylamines; Pl | 2018 |
Elevated trimethylamine
Topics: Aged; Biomarkers; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Diffusion Magnetic Resonance I | 2018 |
Gut Microbiota-Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Brain Ischemia; Cardiovascular Disea | 2018 |
Serum Trimethylamine N-Oxide Concentration Is Positively Associated With First Stroke in Hypertensive Patients.
Topics: Aged; Carnitine; Case-Control Studies; China; Choline; Female; Folic Acid; Gastrointestinal Microbio | 2018 |
Trimethylamine
Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Hos | 2019 |
Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Diabetic Nephropathies; Fema | 2019 |
Serum levels of Trimethylamine-N-oxide in patients with ischemic stroke.
Topics: Aged; Brain Ischemia; Female; Humans; Male; Methylamines; Middle Aged; Risk Factors; Stroke | 2019 |
Prognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke.
Topics: Aged; Brain Ischemia; Female; Humans; Logistic Models; Male; Methylamines; Models, Biological; Progn | 2019 |
Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Bacteria; Carotid Artery Diseases; Case-Control Stud | 2015 |
The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis.
Topics: Aged; Betaine; Biomarkers; Carnitine; Carotid Stenosis; Case-Control Studies; Cause of Death; Chroma | 2016 |
Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiotonic Agents; Case-Control Studies; Female; Gastrointesti | 2017 |